statistiche ricercatore

Continente	#
EU - Europa	623
NA - Nord America	517
AS - Asia	310
SA - Sud America	94
Continente sconosciuto - Info sul continente non disponibili	42
AF - Africa	8
OC - Oceania	1
Totale	1.595

Nazione	#
US - Stati Uniti d'America	505
RU - Federazione Russa	344
SG - Singapore	136
IT - Italia	86
IE - Irlanda	78
BR - Brasile	73
CN - Cina	64
SE - Svezia	45
HK - Hong Kong	35
DE - Germania	18
IN - India	15
BD - Bangladesh	14
VN - Vietnam	14
FR - Francia	11
FI - Finlandia	7
GB - Regno Unito	7
NL - Olanda	7
JP - Giappone	5
LT - Lituania	5
TR - Turchia	5
VE - Venezuela	5
AR - Argentina	4
CA - Canada	4
CO - Colombia	4
AT - Austria	3
EC - Ecuador	3
MX - Messico	3
MY - Malesia	3
PH - Filippine	3
PL - Polonia	3
UA - Ucraina	3
ZA - Sudafrica	3
BH - Bahrain	2
EG - Egitto	2
ES - Italia	2
HN - Honduras	2
ID - Indonesia	2
IL - Israele	2
IQ - Iraq	2
OM - Oman	2
PE - Perù	2
PY - Paraguay	2
AU - Australia	1
BE - Belgio	1
CI - Costa d'Avorio	1
CL - Cile	1
CR - Costa Rica	1
DK - Danimarca	1
EU - Europa	1
JM - Giamaica	1
KE - Kenya	1
KG - Kirghizistan	1
KZ - Kazakistan	1
MK - Macedonia	1
MN - Mongolia	1
NI - Nicaragua	1
NP - Nepal	1
PK - Pakistan	1
SK - Slovacchia (Repubblica Slovacca)	1
TN - Tunisia	1
UZ - Uzbekistan	1
Totale	1.554

Nome	#
Le sindromi miasteniche congenite	240
Which are the factors influencing NIV adaptation and tolerance in ALS patients?	201
Effect of exercise on telomere length and telomere proteins expression in mdx mice	192
Amino acid sequence homology between thyroid autoantigens and central nervous system proteins: Implications for the steroid-responsive encephalopathy associated with autoimmune thyroiditis	166
Severe congenital myasthenic syndrome associated with novel biallelic mutation of the CHRND gene	153
MuSK-Associated Myasthenia Gravis: Clinical Features and Management	150
Endocrine myopathies: Clinical and histopathological features of the major forms	147
Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: A case report	121
Methotrexate as a steroid-sparing agent in myasthenia gravis: A preliminary retrospective study	120
Molecular analysis of SMARD1 patient-derived cells demonstrates that nonsense-mediated mRNA decay is impaired	84
null	21
Totale	1.595

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	72	0	10	0	2	1	0	9	5	1	15	3	26
2022/2023	205	15	25	9	14	8	19	0	8	96	0	7	4
2023/2024	71	4	12	3	5	9	11	5	2	1	9	6	4
2024/2025	294	9	6	2	18	17	8	25	55	59	40	26	29
2025/2026	857	54	51	45	51	70	154	128	117	99	45	16	27
2026/2027	38	15	23	0	0	0	0	0	0	0	0	0	0
Totale													1.595